Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

This study has been terminated.
(Efficacy signals were insufficiently strong to justify recruitment of additional patients.)
Information provided by (Responsible Party):
Janssen Pharmaceutica N.V., Belgium Identifier:
First received: June 3, 2010
Last updated: November 7, 2012
Last verified: November 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 2011
  Estimated Primary Completion Date: No date given
Publications automatically indexed to this study by Identifier (NCT Number):